Zevra Therapeutics Inc
NASDAQ:ZVRA
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
4.23
9
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Wall Street
Price Targets
ZVRA Price Targets Summary
Zevra Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for ZVRA is 21.76 USD with a low forecast of 17.17 USD and a high forecast of 26.25 USD.
ZVRA Last Price Targets
Zevra Therapeutics Inc
The latest public price target was made on Sep 24, 2024 by Jason McCarthy from Maxim Group , who expects ZVRA stock to rise by 189% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.
Analyst | Price Target | Date | Article |
---|---|---|---|
Jason McCarthy
Maxim Group
|
25
USD
Upside 189% |
1 month ago
Sep 24, 2024
|
Zevra Therapeutics, Inc. (ZVRA) PT Raised to $25 at Maxim Group
StreetInsider
|
Jonathan Aschoff
Roth Capital
|
21
USD
Upside 142% |
1 month ago
Sep 24, 2024
|
Zevra Therapeutics price target raised to $21 from $19 at Roth MKM
TheFly
|
Jason Butler
JMP Securities
|
17
USD
Upside 96% |
1 month ago
Sep 24, 2024
|
JMP Securities Starts Zevra Therapeutics, Inc. (ZVRA) at Market Outperform
StreetInsider
|
Oren Livnat
H.C. Wainwright
|
20
USD
Upside 131% |
1 month ago
Sep 23, 2024
|
Zevra Therapeutics, Inc. (ZVRA) PT Raised to $20 at H.C. Wainwright
StreetInsider
|
Sumant Kulkarni
Canaccord Genuity
|
22
USD
Upside 154% |
1 month ago
Sep 18, 2024
|
Zevra Therapeutics, Inc. (ZVRA) PT Lowered to $22 at Canaccord Genuity
StreetInsider
|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is ZVRA's stock price target?
Price Target
21.76
USD
According to Wall Street analysts, the average 1-year price target for ZVRA is 21.76 USD with a low forecast of 17.17 USD and a high forecast of 26.25 USD.
What is Zevra Therapeutics Inc's Revenue forecast?
Projected CAGR
88%
The compound annual growth rate of Zevra Therapeutics Inc's revenue for the next 3 years is 88%.